Effective Study of Live Attenuated Varicella Vaccine to Treat Severe Resistant Psoriasis

Cairo University (CU)

Status and phase: Completed; Phase 4

Conditions: Psoriasis

Treatments: Drug: live attenuated chicken pox vaccine; Drug: saline, efficacy

Study type: Interventional

Funder types: Other

Identifiers

NCT01356004

CairoU

Details and patient eligibility

About

Immunotherapy was reported in the treatment of psoriasis. Treatment of resistant psoriasis may be difficult and cyclosporine can induce some remission.

The investigators hypothesized that the combined use of live attenuated varicella vaccine as an adjuvant therapy to low dose cyclosporine in the treatment of severe resistant psoriasis can give positive responses.

Enrollment: 35 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Severe psoriasis: At least 30% of body involved) according to the rule of nine.
• Resistance to conventional therapy (PUVA, methotrexate, retinoids):

(Maximum PASI 50% improvement while on treatment for a duration not less than 6 months).

• Immunologically competent individuals with
• Seropositive for the varicella antibodies

Exclusion criteria

• Any contraindication to live attenuated varicella vaccine
• Any contraindication to cyclosporine

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

35 participants in 2 patient groups, including a placebo group

chicken pox vaccine, efficacy

Experimental group

Treatment:

Drug: live attenuated chicken pox vaccine

saline, efficacy

Placebo Comparator group

Treatment:

Drug: saline, efficacy